Want to see OMCL full AI Analyst Report?
Top Page
Omnicell
(NASDAQ:OMCL)
Select Model
Select Model
Rating:63Neutral
Price Target:
$40.00
▼(-2.44% Downside)
Action:Reiterated
Date:07/31/26
OMCL’s score is driven primarily by improving financial quality (low leverage and solid, growing free cash flow) and a constructive earnings-call outlook with raised profitability guidance. These positives are tempered by weak technical positioning (trading below major moving averages) and an expensive valuation (very high P/E with no dividend support), which increases sensitivity to any execution or timing risks (tariffs and capital-cycle pacing).
Positive Factors
Balance Sheet Strength
Leverage materially improved to roughly 0.16 with sizable equity relative to assets, giving the company financial flexibility. This cleaner balance sheet reduces refinancing risk, supports capital allocation (R&D, rollouts, buybacks) and underpins stability over the next 2–6 months.
Negative Factors
Thin Net Margins and Profit Volatility
Despite EBITDA recovery, net margins are very slim and past losses highlight earnings volatility. Low net profitability leaves limited cushion for cost shocks or mix shifts, slowing return improvement and making operating leverage benefits vulnerable over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance Sheet Strength
Leverage materially improved to roughly 0.16 with sizable equity relative to assets, giving the company financial flexibility. This cleaner balance sheet reduces refinancing risk, supports capital allocation (R&D, rollouts, buybacks) and underpins stability over the next 2–6 months.
Read all positive factors
Omnicell Key Performance Indicators (KPIs)
Any
Revenue by Segment
Shows how revenue is distributed among various business segments, indicating which areas drive growth and where strategic focus might be needed.
Shows how revenue is distributed among various business segments, indicating which areas drive growth and where strategic focus might be needed.
Data provided by:
The Fly
The FlyOmnicell (OMCL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.61B
Dividend YieldN/A
Average Volume (3M)719.86K
Price to Earnings (P/E)41.4
Beta (1Y)0.59
Revenue Growth8.45%
EPS Growth72.08%
CountryUS
Employees3,525
SectorHealthcare
Sector Strength45
IndustryMedical - Equipment & Services
Share Statistics
EPS (TTM)0.85
Shares Outstanding45,478,910
10 Day Avg. Volume689,632
30 Day Avg. Volume719,864
Financial Highlights & Ratios
PEG Ratio-12.17
Price to Book (P/B)1.69
Price to Sales (P/S)1.76
P/FCF Ratio23.97
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$55.00Price Target Upside34.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)2.26
Revenue Forecast (FY)$1.24B
Omnicell Business Overview & Revenue Model
Company Description
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the h...
How the Company Makes Money
Omnicell makes money primarily by selling medication management and pharmacy automation products, licensing software, and providing ongoing services that support implementation and continued operation.
Key revenue streams typically include:
- Pro...
Omnicell Earnings Call Summary
Earnings Call Date:Apr 28, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Nov 04, 2026
Earnings Call Sentiment Positive
The call conveyed strong operational and financial momentum: robust top-line growth (+15% YoY), outsized improvement in profitability (non-GAAP EBITDA and EPS nearly doubling year-over-year), improved free cash flow, and constructive commercial traction following the Titan XT and OmniSphere launches. Management raised FY profitability guidance while maintaining revenue and bookings targets. Key risks discussed include near-term pacing of Titan XT adoption due to long capital cycles, a $12M tariff headwind, a lower cash balance after debt repayment and buybacks, and some potential quarter-to-quarter margin/revenue variability as expenses are phased throughout the year. On balance, positive execution, raised guidance, and a strong pipeline outweigh the timing and macro/cyclical headwinds.Positive Updates
Top-Line Revenue Growth
Total revenue of $310 million in Q1 FY2026, up 15% year-over-year and finishing at the upper end of prior guidance.
Negative Updates
Lower Cash Balance Versus Prior Year
Cash and cash equivalents declined to $239 million from $387 million a year ago (≈-38%), primarily reflecting the $175 million debt repayment and prior share repurchases, reducing near-term liquidity versus the prior-year level.
Read all updates
Q1-2026 Updates
Positive
Negative
Top-Line Revenue Growth
Total revenue of $310 million in Q1 FY2026, up 15% year-over-year and finishing at the upper end of prior guidance.
Read all positive updates
Company Guidance
Omnicell reiterated and updated its 2026 guidance, giving Q2 revenue of $307–313M (product $174–177M; services $133–136M) with Q2 non‑GAAP EBITDA of $37–42M and non‑GAAP EPS of $0.40–0.48; for full‑year 2026 it maintained product bookings of $510–560M and ARR of $680–700M while guiding total revenue of $1.215–1.255B (product $690–710M; services $525–545M), raised non‑GAAP EBITDA to $153–168M (from $145–165M) and non‑GAAP EPS to $1.80–2.00 (from $1.65–1.85), and disclosed an estimated ~$12M of tariff‑related P&L costs and an assumed non‑GAAP tax rate of ~15%.Omnicell Financial Statement Overview
Summary
Income Statement
64
Positive
Balance Sheet
76
Positive
Cash Flow
72
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.25B | 1.18B | 1.11B | 1.15B | 1.30B | 1.13B |
| Gross Profit | 558.13M | 508.04M | 471.00M | 499.93M | 588.99M | 554.65M |
| EBITDA | 106.06M | 101.87M | 119.87M | 79.98M | 96.85M | 173.33M |
| Net Income | 39.08M | 2.05M | 12.53M | -20.37M | 5.65M | 77.85M |
Balance Sheet | ||||||
| Total Assets | 2.00B | 1.97B | 2.12B | 2.23B | 2.21B | 2.14B |
| Cash, Cash Equivalents and Short-Term Investments | 292.17M | 211.17M | 381.68M | 479.84M | 341.85M | 359.72M |
| Total Debt | 188.51M | 204.34M | 382.55M | 614.09M | 616.74M | 541.01M |
| Total Liabilities | 707.25M | 742.91M | 877.65M | 1.04B | 1.08B | 995.81M |
| Stockholders Equity | 1.29B | 1.23B | 1.24B | 1.19B | 1.13B | 1.15B |
Cash Flow | ||||||
| Free Cash Flow | 141.40M | 86.89M | 151.26M | 139.62M | 17.04M | 202.84M |
| Operating Cash Flow | 182.67M | 127.30M | 187.72M | 181.09M | 77.78M | 231.81M |
| Investing Cash Flow | -57.10M | -60.36M | -52.79M | -55.02M | -58.67M | -412.50M |
| Financing Cash Flow | -240.02M | -218.32M | -235.58M | 23.42M | -20.95M | 47.36M |
Omnicell Technical Analysis
Negative
41.00
Price Trends
42.10
Negative
40.02
Negative
40.35
Negative
Market Momentum
0.08
Positive
42.92
Neutral
11.54
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OMCL, the sentiment is Negative. The current price of 41 is below the 20-day moving average (MA) of 43.24, below the 50-day MA of 42.10, and above the 200-day MA of 40.35, indicating a bearish trend. The MACD of 0.08 indicates Positive momentum. The RSI at 42.92 is Neutral, neither overbought nor oversold. The STOCH value of 11.54 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for OMCL.
Omnicell Risk Analysis
Omnicell disclosed 33 risk factors in its most recent earnings report. Omnicell reported the most risks in the "Production" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Omnicell Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $1.04B | 52.39 | 3.31% | ― | -1.19% | -21.87% | |
65 Neutral | $1.26B | -84.73 | -1.43% | ― | 6.40% | -477.58% | |
64 Neutral | $6.00B | -278.06 | -2.86% | ― | 2.26% | 86.67% | |
63 Neutral | $1.61B | 41.37 | 3.13% | ― | 8.45% | 72.08% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $1.22B | -6.78 | -13.08% | ― | -2.08% | 16.88% | |
47 Neutral | $347.57M | -0.66 | -77.89% | ― | -21.26% | -290.08% |
* Healthcare Sector Average
OMCL
Omnicell
35.37
4.95
16.27%
EVH
Evolent Health
3.09
-6.68
-68.37%
TDOC
Teladoc
6.71
-0.26
-3.73%
TXG
10x Genomics
47.27
33.59
245.54%
GDRX
GoodRx Holdings
3.07
-1.43
-31.78%
CERT
Certara
8.10
-1.84
-18.51%
Omnicell Corporate Events
Business Operations and StrategyExecutive/Board Changes
Omnicell Elevates COO Nnamdi Njoku to President
Positive
Jul 1, 2026
On June 30, 2026, Omnicell’s board appointed Chief Operating Officer Nnamdi Njoku as President, effective July 1, 2026, with CEO and Chairman Randall Lipps stepping down from the president role but retaining his other positions and strategic...
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and ComplianceShareholder Meetings
Omnicell Stockholders Approve Governance Changes and Incentive Plan
Positive
May 26, 2026
On May 19, 2026, Omnicell stockholders held their Annual Meeting and approved all five proposals, including the election of three Class I directors, an advisory endorsement of named executive officer compensation, an expansion of the 2009 Equity I...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.